Systemic light chain amyloidosis myopathy responsive to daratumumab monotherapy.

Diana Maria ChitimusEdouard BerlingLaurent GarderetNadia VenturelliEdoardo MalfattiFrançois Jérôme AuthierGuillaume NicolasPascal LaforêtClaire Lefeuvre

Published in: European journal of neurology (2022)

To our knowledge, this is the first case report of an amyloid myopathy showing a remarkable clinical improvement in response to daratumumab monotherapy. It thereby highlights the potential of daratumumab as a monotherapeutical approach to the treatment of amyloid myopathy complicating AL amyloidosis.

Keyphrases

multiple myeloma
late onset
combination therapy
case report
muscular dystrophy
open label
healthcare
early onset
randomized controlled trial
drug delivery
risk assessment
duchenne muscular dystrophy
study protocol